Now live: Pro — the full 13F research suite for serious investorsSee pricing →
CAXTON CORP

Q1 2024 · 13F-HR

CAXTON CORPholdings as filed

Filed 2024-05-15 · accession 0000919574-24-003094

$17.6M
Reported value
11
Positions
2024-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
98422E103XERSXERIS BIOPHARMA HOLDINGS INC$11.3M64.4%5,113,348CommonSOLE
76200L309RZLTREZOLUTE INC$3.4M19.2%1,318,967CommonSOLE
78462F103SPYSPDR S&P 500 ETF TR$970,9885.53%1,856CommonSOLE
084670702BRK/BBERKSHIRE HATHAWAY INC DEL$428,3082.44%1,019CommonSOLE
501976104KYTXKYVERNA THERAPEUTICS INC$393,6142.24%15,846CommonSOLE
608550208MTEMEURMOLECULAR TEMPLATES INC$306,5801.75%136,866CommonSOLE
60255C885BRD1EURMIND MEDICINE MINDMED INC$273,2071.56%29,065CommonSOLE
00370M103ABVXABIVAX SA$226,0551.29%15,808CommonSOLE
52886X107LXEOLEXEO THERAPEUTICS INC$161,7960.92%10,319CommonSOLE
20454B104CMPXCOMPASS THERAPEUTICS INC$86,0620.49%43,465CommonSOLE
007002108TORCEURADICET BIO INC$41,0960.23%17,488CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.